2 results
Not approvedWill not start
Primary:To compare the efficacy of abrocitinib 200 mg once daily (QD) versus dupilumab (as per label guidelines) in adult participants on background topical therapy with moderate to severe atopic dermatitis (AD).Key SecondaryTo compare the efficacy…
Approved WMOPending
The primary objective is to develop and validate non-invasive portal pressure measurement by MRI in patients with end-stage liverdisease (ESLD).